Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2012-04-02 Capital/Financing Update
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Appendix 3B 8 pages 105.7KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a New Issue Announcement and Application for Quotation of Additional Securities submitted to the ASX. It details the exercise of options by option holders and the subsequent issuance of fully paid ordinary shares. The document includes specifics such as the number of securities issued, exercise price, and terms of the securities. It is a regulatory announcement related to capital changes, specifically the issuance of new shares following option exercises. This type of document fits the category of Capital/Financing Update (CAP) as it reports on changes in the company's capital structure and new share issuance. The document is not a full financial report, earnings release, or management discussion, but a formal announcement of a capital event.
2012-04-02 English
Appointment of Directors 6 pages 35.7KB
Board/Management Information Classification · 100% confidence The document is an announcement dated 7 March 2012 from Biotron Limited regarding the appointment of two new directors, Dr. Susan Pond and Mr. Robert Thomas. It includes detailed biographies of the appointees and an Appendix 3X Initial Director's Interest Notice for each director, which is a regulatory form used to notify the market of a director's interests in securities upon appointment. The content focuses on changes in the company's board of directors and disclosures related to their securities holdings. There is no financial data, earnings information, or report publication mentioned. The document fits the definition of Board/Management Information (MANG) as it announces changes in the company's board of directors.
2012-03-06 English
Option Expiry Notice 3 pages 76.4KB
Share Issue/Capital Change Classification · 95% confidence The document is an Option Expiry Notice from Biotron Limited, dated 29 February 2012, addressed to option holders regarding the expiry of unlisted options on 30 March 2012. It includes instructions on exercising options, payment details, and relevant market price information. The content is a formal announcement to shareholders about the expiry and exercise of options, not a financial report or detailed financial data. It is a notification related to capital structure changes (options exercise), but it is not a full report or financial statement. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes such as option exercises.
2012-02-28 English
Half Yearly Report and Accounts 19 pages 121.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM FINANCIAL REPORT FOR THE HALF YEAR ENDED 31 DECEMBER 2011' and includes detailed financial statements such as the Directors' Report, Condensed Interim Statement of Comprehensive Income, Statement of Financial Position, Cash Flows, Changes in Equity, Notes to the Financial Report, Directors' Declaration, and an Independent Auditor’s Review Report. It references the half year ended 31 December 2011, which is a period shorter than a full fiscal year. The document contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2012
2012-02-27 English
CEO Presentation at International Investor Conference 18 pages 401.6KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by the CEO of Biotron Limited at an international investor conference, specifically the BIO CEO and Investor Conference held in New York in February 2012. It includes extensive information about the company's strategy, drug development pipeline, clinical trial results, market opportunities, and financial highlights. The content is structured as a presentation with slides and detailed explanations, focusing on financials, strategy, and market position. There is no indication that this is an official regulatory filing, annual or interim report, or an announcement of voting results or management changes. The document is not a transcript of a call but a prepared presentation for investors. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (11,482 characters) and detailed content support this classification with high confidence.
2012-02-14 English
Appendix 4C - quarterly 5 pages 52.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and compliance statements. The document covers a quarterly period ending 31 December 2011 and includes substantive financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements. The document is not a brief announcement or a certification, but a full quarterly financial report. Q2 2012
2012-01-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.